Abstract
There are four old and well established vaccines for bacterial infections in children: the vaccines against diphtheria, tetanus, tuberculosis and whooping cough (pertussis). Their value has been amply proven and they are now the mainstay of the Expanded Programme of Immunization (EPI) of the WHO, recommended to be given to each infant born in the world. Their actual usage covers roughly two thirds of the world’s children and is rapidly increasing through collaborative efforts of EPI. The EPI framework would give an excellent opportunity to introduce new vaccines to rapidly benefit children in all countries. Do we have such vaccines ready? For which diseases would new vaccines be needed (Institute of Medicine, 1986; Griffiss et al, 1987; Robbins and Freeman, 1988)?
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Acharya, V.L., Lowe, C.U., Thapa, R., Gurubacharya, V.L., Shrestha, M.B., Cadoz, M., Schulz, D., Armand, J., Bryla, D., Trollfors, B., Gramton, T., Schneerson, R. and Robbins, J.B., 1987, Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report, N.Engl.J.Med., 317:1101.
Anderson, P., 1984, The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type B, J.Infect.Dis., 149:1034.
Anderson, P. and Insel, R.A., 1988, Prospects for overcoming maturational and genetic barriers to the human antibody response to the capsular polysaccharide of Haemophilus influenzae type b, Vaccine, 6:188.
Anderson, P.W., Pichichero, M.E., Insel, R.A., Betts, R., Eby, R. and Smith, D.H., 1986, Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant, J.Immunol., 137:1181.
Anderson, P., Pichichero, M.E. and Insel, R.A., 1985, Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diptheria toxoid or CRM197, J.Clin.Invest., 76:52.
Artenstein, M.S., Gold, R., Zimmerly, J.G., Wyle, F.A., Schneider, H. and Harkins, C., 1970, Prevention of meningococcal disease by group C polysaccharide vaccine, N.Engl.J.Med., 282:417.
Austrian, R., Douglas, R.M., Schiffman, G., Coetzee, A.M., Koornhof, H.J., Hayden-Snith, S. and Reid, R.D.W., 1976, Prevention of pneumococcal pneumonia by vaccination, Trans.Assoc.Am.Physicians, 89:184.
Baker, C.J., 1990, Immunization to prevent group B Streptococcal Disease: victories and vexations, J.Infect.Dis., 161:917.
Baker, C.J., Rench, M.A., Erwards, M.S., Carpenter, R.J., Hays, B.M. and Kasper, D.L., 1988, Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus, N.Engl.J.Med., 319:1180.
Band, J.D., Fraser, D.W. and Ajello, G., 1984, Haemophilus influenza disease study group. Prevention of Haemophilus influenzae type b disease, JAMA, 251:2381.
Beuvery, E.C., van Rossum, F. and Nagle, J., 1982, Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates, Infect.Immun., 37:15.
Bolan, G., Broome, C.V., Facklam, R.R., Plikaytis, B.D., Fraser, D.W. and Schlech, W.F., 1986, Pneumococcal vaccine efficacy in selected populations in the United States, Ann.Intern.Med., 104:1.
Chu, C.Y., Schneerson, R., Robbins, J.B. and Rastogi, S.C., 1983, Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates, Infect.Immunol., 40:245.
Claesson, B.A., Trollfors, B., Lagergard, T., Taranger, J., Bryla, D., Otterman, G., Cramton, T., Yang, Y., Reimer, C.R., Robbins, J.B. and Schneerson, R., 1988, Clinical and immunological responses to the capsular polysaccharide of Haemophilus influenzae type alone or conjugated to tetanus toxoid in 18 to 23 month old children, J.Pediatr., 112:695..
Clemens, J.D., Sack, D.A., Harris, J.R., Chakraborty, J., Khan, M.R., Stanton, B.F., Ali, M., Ahmed, F., Yunus, M. and Kay, B.A., 1988a, Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrheal illness and mortality in an area endemic for cholera, Lancet, i:1375.
Clemens, J.D., Sack, D.A., Harris, J.R., Chakraborty, J., Neogy, P.K., Stanton, B., Hilda, N., Khan, M.U., Kay, B.A., Khan, R., Ansaruzzaman, M., Yunus, M., Rao, M.R., Svennerholm, A-M. and Holmgren, J., 1988b, Cross-protection by B subunit whole-cell cholera vaccine against diarrhoea associated with heat-labile toxin producing enterotoxigenic Escherichia coli: results of a large scale field trial, J.Infect.Dis., 158:372.
Daum, R.S., Marcuse, E.K., Giebink, G.S., Hall, C.B., Lepow, M.L., McCracken, G.H., Peter, G., Phillips, C.F., Wright, H.T. and Plotkin, S.A., 1988, Haemophilus influenzae type b vaccines: lessons from the past, Pediatrics, 81:893.
Einhorn, M.S., Weinberg, G.A., Anderson, E.L., Granoff, P.D. and Granoff, D.M., 1986, Immunogenicity in infants of Haemophilus influenzae type b polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein, Lancet, ii:299.
Eskola, J., Peltola, H., Takala, A.H., Kayhty, H., Hakulinen, M., Karanko, V., Kela, E., Rekola, P., Ronnberg, P-R., Samuelson, J.S., Gordon, L.K. and Makela, P.H., 1987, Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy, N.Engl.J.Med., 317:717.
Eskola, J., Kayhty, H., Peltola, H., Karanko, V., Makela, P.H., Samuelson, J. and Gordon, L.K., 1985, Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide/diphtheria toxoid conjugate vaccine, Lancet, i:1184.
Ferreccio, C., Levine, M.M., Rodriguez, H. and Contreras, R., 1989, Comparative efficacy of two, three or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules. A field trial in an endemic area, J.Infect.Dis., 159:766.
Finne, J., Leinonen, M. and Makela, P.H., 1983, Antigenic similarities between brain components and bacteria causing meningitidis. Implications for vaccine development and pathogenesis, Lancet, ii:355.
Fothergill, L.D. and Wright, J., 1933, Influenzal meningitis: relation of age incidence to the bactericidal power of blood against the causal organisms, J.Immunol., 24:273.
Gold, R.C., Lepow, M.L., Goldschneider, I., Draper, T.F. and Gotschlich, E.C., 1975, Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants, J.Clin.Invest., 56:1536.
Gordon, L.K., 1984, Characterization of a hapten-carrier conjugate vaccine: H. influenzae-diphtheria conjugate vaccine, in Chanock, R.M. and Lerner, R.A., eds., Modern Approaches to Vaccines, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
Gotschlich, E.C., Goldschneider, I. and Artenstein, M.S., 1969a, Human immunity to the meningococcus. V. The effect of immunization with the meningococcal group C polysaccharide on the carrier state, J.Exp.Med., 129:1385.
Gotschlich, E.C., Liu, T.Y. and Artenstein, M.S., 1969b, Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharide, J.Exp.Med., 129:1349.
Granoff, D.M. and Basden, M., 1980, Hemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race and contact with a case on incidence of disease, J.Infect.Dis., 141:40.
Greenwood, B.M., Hassan-King, M., Whittle, H.C., 1978, Prevention of secondary cases of meningococcal disease in household contacts by vaccination, Br.Med.J., 1:1317.
Greenwood, B.M. and Wali, S.S., 1980, Control of meningococcal infection in the African meningitis belt by selective vaccination, Lancet, i:729.
Griffiss, J.M., Apicella, M.A., Greenwood, B. and Makela, P.H., 1987, Vaccines against encapsulated bacteria: a global agenda, R.Infect.Dis., 9:176.
Herva, E., Luotonen, J., Timonen, M., Sibakov, M., Karma, P. and Makela, P.H., 1980, The effect of polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal carriage of streptococcus pneumoniae, Scand.J.Infect.Dis., 12:97.
Institute of Medicine, ed., 1986, New Vaccine Pevelopment, Establishing Priorities, Volume II, Piseases of importance in developing countries, Washington, P.C., National Academy Press.
Jann, K. and Jann, B., 1985, Cell surface components and virulence: Escherichia coli O and K antigens in relation to virulence and pathogenicity, in: The Virulence of Escherichia coli, Soc.Gen.Microbiol.
Jennings, H. and Lugowski, C., 1981, Immunochemistry of groups A, B and C meningococcal polysaccharide tetanus toxoid conjugates, J.Immunol., 127:104.
Karma, P., Pukander, J. and Sipila, M., 1985, Prevention of otitis media in children by pneumococcal vaccination, Am.J.Otolaryngol., 6:173.
Kayhty, H., Karanko, V., Peltola, H., Sarna, H. and Makela, P.H., 1980, Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children, J.Infect.Dis., 142:861.
Kayhty, H., Peltola, H., Karanko, V. and Makela, P.H., 1983, The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b, J.Infect.Dis., 147:1100.
Kayhty, H., Karanko, V., Peltola, H and Makela, P.H., 1984, Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory, Pediatrics, 74:857.
Kayhty, H., Eskola, J., Peltola, H., Stout, M.G., Samuelson, J.S. and Gordon, L.K., 1987, Immunogenicity in infants of Haemophilus influenzae type b capsular polysaccharide mixed with PTP or conjugated to diphtheria toxoid, J.Infect.Dis., 155:100.
Kayhty, H., Makela, O., Eskola, J., Saarinen, L. and Seppala, I., 1988, Isotype distribution and bacteridal activity of antibodies after immunization with Haemophilus influenzae type b vaccines at 18–24 months of age, J.Infect.Dis., 158:973.,
Kayhty, H., Peltola, H., Eskola, J., Ronnberg, P-R., Kela, E., Karanko, V. and Makela, P.H., 1989, Immunogenicity of Haemophilus influenzae oligosaccharide-protein and polysaccharide-protein conjugate vaccination of children at 4, 6 and 14 months of age, Pediatrics, 84:995.
King, S.P., Ramlal, A., Wynter, H., Moodie, K., Castle, P., Kuo, J.S.C., Barnes, L. and Williams, C.L., 1981, Safety and immunogenicity of a new Haemophilus influenzae type b vaccine in infants under one year of age. Lancet, ii:705.
Klein, J.O., 1981, The epidemiology of pneumococcal disease in infants and children, Rev.Infect.Dis., 3:246.
Koskela, M., 1986, Antibody response of young children to parenteral vaccination with pneumococcal capsular polysaccharides: a comparison between antibody levels in serum and middle ear effusion, Pediatr.Infect.Dis. t 5:431.
Lapeyssonnie, L., 1963, La méningite cérébro-spinale en Afrique, Bull.Wld.Hlth.Org., 28, Suppl.
Leinonen, M., Frasch, C.E., 1982, Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: Use of polylysine precoating in an enzyme-linked immunosorbent assay, Infect.Immun., 38:1203.
Leinonen, M., Sakkinen, A., Kalliokoski, R., Luotonen, J., Timonen, M., Mäkela, P.H., 1986, Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children, Pediatr.Infect.Dis., 5:39.
Levine, M.M., Ferreccio, C., Black, R.E. and Germanier, R., 1987a, Large-scale field trial of Ty21a live oral typhoid vaccine in entericcoated capsule formulation, Lancet, i:1049.
Levine, M.M., Harrington, D., Murphy, J.R., Morris, J.G., Losonsky, G., Tall, B., Lindberg, A.A., Svenson, S., Bagar, S., Edwards, M.F. and Stocker, B., 1987b, Safety, infectivity, immunogenicity and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in man, J.Clin.Invest., 79:888.
Lindberg, A.A., Karnell, A., Pap, T., Sweiha, H., Hultenby, K. and Stocker, B., 1990, Construction of an auxotrophic Shigella flexneri strain for use as a live vaccine, M.Pathogen., 8, in press.
Losonsky, G.A., Santosham, M., Sehgal, V.M., Zwahlen, A. and Moxon, R., 1984, Haemophilus influenzae disease in the White Mountain Apaches: Molecular epidemiology of a high risk population, Pediatr.Infect.Dis., 3:539.
Makela, O., Mattila, P., Rautonen, N., Seppala, I., Eskola, J. and Kayhty, H., 1987, Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid), J.Immunol., 139:1999.
Michaels, R.H., Poziviak, C.S., Stonebraker, F.E., Norden, C.W., 1976, Factors affecting pharyngeal Haemophilus influenzae type b colonization rates in children, J.Clin.Microbiol., 4:413.
Paton, J.C., Lock, R.A. and Hansman, D.J., 1983, Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae, Infect.Immun., 40:548.
Peltola, H., 1987, Meningococcal disease: an old enemy in Scandinavia, in: Evolution of Meningococcal Disease, vol. I, Vedros, N.A., ed., University of California, Berkeley.
Peltola, H., Kayhty, H., Sivonen, A. and Makela, P.H., 1977a, Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double blind study of 100,000 vaccinées three months to five years of age in Finland, Pediatr., 60:730.
Peltola, H., Makela, P.H., Kayhty, H., Jousimies, H., Herva, E., Hallstrom, K., Sivonen, A., Renkonen, O-V., Pettay, O., Karanko, V., Ahvonen, P. and Sarna, S., 1977b, Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age, N.Engl.J.Med., 297:686.
Peltola, H., Kayhty, H., Virtanen, M. and Makela, P.H., 1984, Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine, N.Engl.J.Med., 310:1561.
Pichichero, M.E. and Insel, R.A., 1983, Mucosal antibody response to parenteral vaccination with Haemophilus influenzae type b capsule, J.Allergy.Clin.Immunol., 72:481.
Reingold, A.L., Broome, C.V., Hightower, A.W., Ajello, G.W., Bolan, G.A., Adamsbaum, C., Jones, E.E., Phillips, C., Tiendrebeogo, H. and Yada, A., 1985, Age specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine, Lancet, ii:114.
Riley, I.D., Everingham, F.A., Smith, D.E. and Douglas, R.M., 1981, Immunization with a polyvalent pneumococcal vaccine. Effect of respiratory mortality in children living in the New Guinea highlands, Arch.Dis.Child., 56:354.
Robbins, A. and Freeman, P., 1988, Obstacles to developing vaccines for the Third World, Sci.Am., 259:90.
Robbins, J.B., Parke, J.C., Schneerson, R. and Whisnant, J.K., 1973, Quantitative measurement of “natural” and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies, Pediatr., 7:103.
Robbins, J.B., Austrian, R., Lee, C-J., Rastogi, S.C., Schiffman, G., Henrichsen, J., Makela, P.H., Broome, C.V., Facklam, R.R., Tiesjema, R.H. and Parke, J.C., Jr., 1983, Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups, J.Infect.Dis., 148:1136.
Rosen, C., Christensen, P., Hovelius, B. and Prellner, K., 1984, A longitudinal study of the nasopharyngeal carriage of pneumococci as related to pneumococcal vaccination in children attending day care centres, Acta Otolaryngol. (Stocfch.), 98:524.
Sarnesto, A., Ranta, S., Vaananen, P. and Makela, O., 1985, Proportions of Ig classes and subclasses in rubella antibodies, Scand.J.Immunol., 21:275.
Saukkonen, K., Haltia, M., Frosch, M., Bitter-Suerman, D. and Leinonen, M., 1986, Antibodies to the capsular polysaccharide of Neisseria meningitidis group B or E. coli K1 bind to the brains of infant rats in vitro but not in vivo, Microb.Path., 1:101.
Schneerson, R., Barrera, O., Sutton, A. and Robbins, J.B., 1980, Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates, J.Exper.Med., 152:361.
Seppala, I.J.T., Rautonen, N., Sarnesto, A., Mattila, P.A. and Makela, O., 1984, The percentages of six immunoglobulin isotypes in human antibodies to tetanus toxoid: standardization of isotype-specific second antibodies in solid-phase assay, Eur. J. Immunol., 14:868.
Seppala, I., Sarva, H., Makela, O., Mattila, P., Eskola, J. and Kayhty, H., 1988, Human antibody responses to two conjugate vaccines of Haemophilus influenzae type b saccharides and diphtheria toxin, Scand.J.Immunol., 28:71.
Shann, F., 1986, Etiology of severe pneumonia in children in developing countries, Pediatr.Infect.Dis., 5:247.
Shann, F., Germer, S., Hazlett, P., Gratter, M., Linneman, V. and Payne, R., 1984, Aetiology of pneumonia in children in Goroka Hospital, Papua, New Guinea, Lancet, ii:537.
Szu, S.C., Stone, A.L., Robbins, J.P., Schneerson, R. and Robbins, J.B., 1987, Preparation and characterization of conjugates of the Vi capsular polysaccharide and carrier proteins, J.Exp.Med., 166:1510.
Szu, S.C., Li, X., Schneerson, R., Vickers, J.H., Bryla, P. and Robbins, J.B., 1989, Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or tis b subunit as a carrier bound to high- or lower-molecular-weight Vi, Infect.Immun., 57:3823.
Takala, A.K., 1989, Epidemiologic characteristics and risk factors for invasive Haemophilus influenzae type b disease in a population with high vaccine efficacy, Pediatr.Infect.Dis., 8:343.
Takala, A.K., Eskola, J., Peltola, H. and Makela, P.H., 1989, Epidemiology of invasive Haemophilus influenzae type b disease among children in Finland before vaccination with Haemophilus influenzae type b conjugate vaccine, Pediatr.Infect.Dis.J., 8:297.
Takala, A.K., Eskola, J., Nissinen, A., Leinonen, M., Pekkanen, E. and Makela, P.H., 1990, Effect of vaccination with Haemophilus influenzae type b (Hib) conjugate vaccine on the oropharyngeal carriage of Hib, 30th ICAAC, Atlanta, Ga.
Todd, J.K. and Bruhn, F.W., 1975, Severe H. influenzae infections: spectrum of disease, Am.J.Dis.Child., 129:607.
Wahdan, M.H., Serie, C., Cerisier, Y., Sallam, S. and Germanier, R., 1982, A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: Three years1 results, J.Infect.Dis., 145:292.
Ward, H. and Cochi, S.L., 1988, Haemophilus influenzae vaccines, in: Vaccines, Plotkin, S.A., Mortimer, E.A., eds., W.B. Saunders Co., Philadelphia.
Ward, H., Margolis, H.S., Lum, M.K.W., Fraser, D.W., Bender, T.R. and Anderson, P., 1981, Haemophilus influenzae disease in Alaskan eskimos: Characteristics of a population with an unusual incidence of invasive disease, Lancet, i:1281.
Ward, J.I., Broome, C.V., Harrison, L.H., Shinefield, H. and Black, S., 1988, Haemophilus influenzae type b vaccines: lessons for the future, Pediatrics, 81:887.
Ward, J., Breimeman, G., Letson, W. and Heyward, W.L., 1990, Alaska H. influenzae vaccine study group. Limited efficacy of an Haemophilus influenzae type b conjugate vaccine (PRP-D) in Alaskan native infants immunized at 2, 4 and 6 months of age, N.Engl.J.Med., in press.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Makela, P.H., Kayhty, H., Takala, A.K., Peltola, H., Eskola, J. (1991). Vaccines Against Bacterial Infections of Children. In: Gregoriadis, G., Allison, A.C., Poste, G. (eds) Vaccines. NATO ASI Series, vol 215. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3848-6_14
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3848-6_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6717-8
Online ISBN: 978-1-4615-3848-6
eBook Packages: Springer Book Archive